Genomics

Dataset Information

0

Telomerase upregulation induces progression of mouse BrafV600E-driven thyroid cancers and triggers non-telomeric effects


ABSTRACT: Mutations in the promoter of the telomerase reverse transcriptase (TERT) gene are the paradigm of a cross-cancer alteration in a non-coding region. TERT promoter mutations (TPMs) are biomarkers of poor prognosis in cancer, including thyroid tumors. TPMs enhance TERT transcription, which is otherwise silenced in adult tissues, thus reactivating a bona fide oncoprotein. To study TERT deregulation and its downstream consequences, we generated a Tert mutant promoter mouse model via CRISPR/Cas9 engineering of the murine equivalent locus (Tert-123C>T) and crossed it with thyroid-specific BrafV600E-mutant mice. We also employed an alternative model of Tert overexpression (K5-Tert). Whereas all BrafV600E animals developed well-differentiated papillary thyroid tumors, 29% and 36% of BrafV600E+Tert-123C>T and BrafV600E+K5-Tert mice progressed to poorly differentiated cancers at week 20, respectively. Tert-upregulated tumors showed increased mitosis and necrosis in areas of solid growth, and older animals displayed anaplastic-like features, i.e., spindle cells and macrophage infiltration. Murine Tert promoter mutation increased Tert transcription in vitro and in vivo, but temporal and intra-tumoral heterogeneity was observed. RNA-sequencing of thyroid tumor cells showed that processes other than the canonical Tert-mediated telomere maintenance role operate in these specimens. Pathway analysis showed that MAPK and PI3K/AKT signaling, as well as processes not previously associated with this tumor etiology, involving cytokine and chemokine signaling, were overactivated. These models constitute useful pre-clinical tools to understand the cell-autonomous and microenvironment-related consequences of Tert-mediated progression in advanced thyroid cancers and other aggressive tumors carrying TPMs. Implications: Telomerase-driven cancer progression activates pathways that can be dissected and perhaps therapeutically exploited.

ORGANISM(S): Mus musculus

PROVIDER: GSE227539 | GEO | 2023/08/01

REPOSITORIES: GEO

Similar Datasets

2021-04-06 | GSE171473 | GEO
2017-02-27 | GSE77265 | GEO
2010-09-10 | E-GEOD-23216 | biostudies-arrayexpress
2010-09-10 | GSE23216 | GEO
2023-11-04 | PXD037776 | Pride
2012-01-17 | E-GEOD-35045 | biostudies-arrayexpress
2012-01-17 | E-GEOD-35046 | biostudies-arrayexpress
2019-09-16 | E-MTAB-8248 | biostudies-arrayexpress
2012-01-17 | E-GEOD-35044 | biostudies-arrayexpress
2015-04-23 | E-GEOD-60175 | biostudies-arrayexpress